B. J. Gertz
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)
Publications by Year
Research Areas
Bone health and treatments, Bone health and osteoporosis research, Growth Hormone and Insulin-like Growth Factors, Bone and Joint Diseases, Inflammatory mediators and NSAID effects
Most-Cited Works
- → Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine(1994)201 cited
- → The effect of short term treatment with alendronate on vertebral density and biochemical markers of bone remodeling in early postmenopausal women.(1993)171 cited
- → Clinical pharmacology of alendronate sodium(1993)161 cited
- → Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal‐salt diet(2002)158 cited
- → Effects of a novel cholecystokinin (CCK) receptor antagonist, MK-329, on gallbladder contraction and gastric emptying in humans. Implications for the physiology of CCK.(1989)157 cited
- → Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis(2001)147 cited
- → Application of a New Serum Assay for Type I Collagen Cross-Linked N-Telopeptides: Assessment of Diurnal Changes in Bone Turnover With and Without Alendronate Treatment(1998)118 cited
- → Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6.(1993)98 cited
- Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile.(1997)
- → Pharmacokinetics, COX-2 specificity, and tolerability of supratherapeutic doses of rofecoxib in humans(2000)93 cited